Full-Time
Lead Project Manager
PSI CRO
1,001-5,000 employees
Global CRO delivering on-time patient enrollment
Compensation Overview
CA$160k - CA$170k/yr
Remote in Canada
Remote
 Project & Program Management (1) |
|---|
Get referred to PSI CRO
See people who can refer or advise you
- At least 5-year industry experience in clinical research
- At least 2 years of project-level clinical project management experience, including management of all project phases from startup to closure
- Manage small (<5 countries and/or limited services) and medium sized (5-15 countries and/or full service) projects under general supervision with primary responsibility for the production of project deliverables in conformance with the predefined quality standards, on time and on budget
- Perform the project co-manager’s role in complex international projects/programs with secondary responsibility for the production of project deliverables in conformance with the predefined quality standards, on time and on budget
- Adhere to and promotion of principles of delivery and service in dealing with PSI customers
- Project team leadership
- Training, mentoring and coaching of study team members
- Participation in feasibility research
- Assistance in business development tasks, such as development of proposals, client presentations, bid defense meetings, and the like
- Implementation of company standard practices and compliance with intradepartmental procedures
- Experience in Oncology is preferred
- Experience in Gastroenterology and/or radiopharmaceuticals is a plus
PSI CRO is a global contract research organization that handles clinical trials for multiple therapeutic areas, with a focus on enrolling patients on schedule and delivering studies on time. Its services span feasibility assessments, trial planning, site selection, patient recruitment, and multi-continent trial execution across 50+ countries, backed by medical doctor resources dedicated to accurate timeline predictions. Unlike many CROs, PSI emphasizes predictable enrollment and on-time project delivery, aiming for high client satisfaction and repeat business through a pragmatic, no-nonsense approach. The company’s goal is to be regarded as the best CRO in the world by both clients and employees, achieved through reliable timelines, strong execution, and low staff turnover.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Switzerland
Founded
1995
Get referred to PSI CRO
See people who can refer or advise you
Simplify's Take
What believers are saying
- Toronto expansion in January 2026 deepens PSI's North American delivery capacity.
- Beijing's April 2026 launch improves access to Chinese regulators and investigator networks.
- SYNETIC reduces non-enrolling site waste, saving studies millions in recruitment costs.
What critics are saying
- IQVIA, ICON, and Parexel can copy PSI's AI site-selection advantage quickly.
- Beijing and Toronto offices raise fixed costs if sponsor demand softens in 2026.
- A major sponsor loss would crush utilization and threaten PSI's global CRO model.
What makes PSI CRO unique
- PSI CRO opened Beijing in April 2026 to stay close to Chinese regulators.
- PSI CRO operates a 58-country platform with 3,200-plus employees worldwide.
- SYNETIC cuts site identification from six weeks to minutes with explainable AI.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Company News
From Shanghai to Beijing: PSI CRO expands its footprint in China with a new Beijing office. Beijing, China - April 28, 2026 - PSI CRO, a Swiss-based global full-service contract research organization, today announced the opening of its second office in China, located in China World Tower B in Beijing's Chaoyang District. In 2019, PSI established its first China office in Shanghai, where the local team has steadily grown while supporting sponsors across the region. By adding a Beijing location, PSI brings its team closer to key drug regulatory authorities and leading research institutions. China is playing an increasingly important role in global clinical development, creating a growing need for strong local operational and regulatory support. PSI's presence in Beijing helps meet that need, combining local expertise with coordinated global teams to support clear decision-making and predictable, on-time delivery for sponsors. For PSI, the Beijing office represents a targeted investment to support clients where it matters most - close to regulators, close to investigator sites, and close to strategic partners.
PSI CRO, a global clinical research organisation, has reduced clinical trial site identification from up to six weeks to minutes using SYNETIC, an AI knowledge engine powered by the Arango Contextual Data Platform. The system helps identify higher-performing trial sites and minimise costly non-enrolling institutions, which account for 30-40% of trial sites. Clinical trials can cost over $160 per minute operationally, and activating a trial site costs $30,000 or more. With 15% of sites never enrolling a single patient, failed recruitment can cost millions per study. SYNETIC unifies fragmented clinical research data into a single contextual layer, preserving relationships across investigators, institutions, protocols and historical outcomes. The platform provides explainable AI recommendations, including rationale, supporting evidence and confidence levels, enabling data-driven site selection in minutes rather than weeks.
PSI CRO strengthens Canadian presence with new Toronto office and leadership role. PSI CRO has broadened its footprint in Canada by opening a new office in the Toronto area and naming an experienced industry leader to guide its operations there. The office, located in Mississauga, Ontario, builds on the company's established Canadian presence and commitment to clinical research excellence. PSI CRO has been active in Canada for over a decade, supporting complex clinical trials with a focus on dependable delivery and strong relationships with research sites. As part of this expansion, David Allen, MBA, has been appointed as Country Manager for Canada. Allen brings more than 30 years of experience in clinical research from both sponsor and CRO environments. In his new role, he will lead efforts to enhance the company's operational capabilities in the local market and ensure alignment with PSI's global standards for on-time trial execution. PSI's continued growth in North America reflects broader trends of increasing trial activity in the region, particularly for pivotal phase II and phase III studies where precision and efficiency are critical. The expanded Toronto operations aim to further support sponsors with rigorous trial planning and execution.
TOKYO, 14 March 2025 - PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the appointment of Sayaka Kaji as Country Manager for Japan.
Psi CRO Ag launched a CRA Academy to provide to help its team members develop therapeutic expertise as well as soft skills to manage key relationships with sites.